BioSpace News Archive

It’s exciting and quite an honor to have an opportunity to be interviewed by Kathy Ireland on Worldwide Business and to share the corporate vision that we have at Sino Biological.

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, welcomed the topline data shared today from an open-label study of psilocybin therapy for depression in cancer patients.

ImCheck Therapeutics announced today the publication of the preclinical to clinical development of its lead immuno-oncology program, ICT01.

OliX Pharmaceuticals, Inc. today announced that the Company has selected Pharmaron to conduct non-clinical toxicity studies to evaluate the safety of OLX703A, OliX’s investigational therapeutic for hepatitis B (HBV).

Parexel, a leading global clinical research organization (CRO) focused on development and delivery of innovative new therapies to advance patient health, and Kyoto University Hospital today announced a strategic alliance aimed at providing more opportunities for clinical research and producing efficient and productive ways of supporting clinical studies.

Intellia Therapeutics, Inc. (NASDAQ:NTLA), today announced new data supporting novel capabilities of its CRISPR/Cas9 genome editing platform, which the Company plans to leverage for the development of future therapeutic candidates.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2021 financial results on Wednesday, November 3, 2021.

SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), today announced that it has entered into a collaboration agreement with Ab Magnitude Ventures Group, LLC and Ab Magnitude Fund, LP (collectively, “Ab Magnitude”) for the development of next-generation targeted oncology therapeutics.

Monte Rosa Therapeutics, Inc. today announced that Sharon Townson, Ph.D., Chief Technology Officer, will present at the virtual 4th Annual Targeted Protein Degradation Summit on Wednesday, Oct. 27 at 11:45 a.m. ET.

Fluidigm Corporation today announced that it will report third quarter 2021 financial results on Monday, November 8, 2021, after the close of the market. Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will host a conference call and webcast at 1:30 p.m. PT, 4:30 p.m. ET